HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Extramammary Paget's disease of skin — Clinical Guidelines

Overview

Extramammary Paget's disease (EMPD) is a rare intraepidermal adenocarcinoma that primarily affects the skin of the genital and perianal regions, though it can occur in other areas such as the axilla and groin. It is characterized by atypical cells resembling Paget cells that infiltrate the epidermis without dermal invasion, often leading to chronic, persistent skin lesions that can be locally destructive. EMPD is clinically significant due to its potential for local recurrence and distant metastasis, particularly to lymph nodes and bones. It predominantly affects older adults, with a median age at diagnosis around 60-70 years, and has a slight male predominance. Recognizing EMPD early is crucial in day-to-day practice to prevent complications and improve patient outcomes through timely intervention 1.

Pathophysiology

EMPD arises from the transformation of apocrine sweat gland cells or hair follicle cells, leading to the proliferation of malignant cells within the epidermis. The molecular pathogenesis involves genetic alterations, including mutations in TP53, PIK3CA, and ERBB2, which disrupt normal cellular regulatory mechanisms and promote uncontrolled growth 1. These genetic changes often result in aberrant signaling pathways, such as the PI3K/AKT/mTOR and HER2 pathways, contributing to the characteristic intraepidermal spread and potential for deeper invasion and metastasis. The progression from benign to malignant transformation is gradual, often masked by chronic inflammatory changes and the indolent nature of the disease, making early diagnosis challenging 1.

Epidemiology

EMPD is a rare condition with an estimated annual incidence of approximately 1 to 2 cases per million population. It predominantly affects individuals over the age of 50, with a male-to-female ratio ranging from 2:1 to 4:1. Geographic distribution does not show significant variations, but certain risk factors such as chronic irritation or inflammation may predispose individuals to its development. Over time, there is no clear trend indicating an increase or decrease in incidence, though improved diagnostic techniques may contribute to more frequent identification 1.

Clinical Presentation

Patients with EMPD typically present with persistent, scaly, erythematous, or hyperpigmented plaques in the genital, perianal, or perineal regions. These lesions often have a chronic course, evolving slowly over months to years. Common symptoms include pruritus, pain, and bleeding, especially if the lesions become ulcerated. Atypical presentations may mimic inflammatory dermatoses or other malignancies, necessitating careful clinical evaluation. Red-flag features include rapid progression, ulceration, and involvement of atypical sites, which warrant urgent diagnostic workup 1.

Diagnosis

The diagnosis of EMPD involves a combination of clinical suspicion, histopathological examination, and immunohistochemical staining. Clinically, the characteristic appearance of persistent, poorly demarcated plaques in typical locations guides initial suspicion. Histopathological examination is definitive, showing intraepidermal proliferation of large, pale-staining cells with abundant pale cytoplasm and large nuclei, often referred to as Paget cells. Key diagnostic criteria include:

Histopathology: Intraepidermal spread of large, pleomorphic cells with characteristic Paget cell morphology.

Immunohistochemistry: Positive staining for cytokeratins (e.g., CK20, CK7) and often negative for S100 protein, distinguishing it from other cutaneous malignancies.

Excisional Biopsy: Recommended for definitive diagnosis and staging.

Differential Diagnosis: Rule out conditions like psoriasis, eczema, Bowen's disease, and other intraepidermal carcinomas through clinical context and pathology.

Imaging: CT or MRI for staging, particularly if regional lymphadenopathy or distant metastases are suspected.

Differential Diagnosis:

Psoriasis: Typically presents with well-demarcated scaly plaques and negative Paget cell markers.

Bowen's Disease: Intraepidermal squamous cell carcinoma without dermal invasion, often positive for CK5/6 but negative for CK20.

Seborrheic Dermatitis: Characterized by greasy, yellowish scales and responds to antifungal treatments, unlike EMPD 1.

Management

First-Line Treatment

Surgical Excision: Wide local excision with clear margins is the primary treatment for localized EMPD. The goal is to achieve negative margins to minimize recurrence risk.

Procedure: Wide local excision with 1-2 cm margins.

Follow-Up: Regular dermatologic follow-up to monitor for recurrence.

Second-Line Treatment

Radiation Therapy: Indicated for cases with positive margins, extensive disease, or when surgery is not feasible.

Modality: External beam radiation therapy (EBRT).

Dose: Typically 50-60 Gy in fractions.

Monitoring: Regular assessment for radiation side effects and disease response.

Refractory or Metastatic Disease

Systemic Therapy: For metastatic or recurrent disease, systemic treatments are essential.

Chemotherapy: Platinum-based regimens (e.g., cisplatin) or taxanes may be considered.

Targeted Therapy: Imatinib has shown efficacy in some cases, particularly in HER2-positive EMPD.

- Dose: 400 mg daily. - Duration: Until disease progression or unacceptable toxicity.

Immunotherapy: Emerging role, particularly with PD-1 inhibitors, though data are limited.

- Dose: Standard doses based on approved regimens (e.g., pembrolizumab 2 mg/kg every 3 weeks). - Monitoring: Regular imaging and biomarker assessments.

Contraindications:

Severe renal or hepatic impairment may limit certain chemotherapeutic agents.

Specific drug interactions and patient comorbidities must be considered 1.

Complications

Local Complications: Recurrent disease, chronic ulceration, and significant cosmetic/functional impairment.

Management Triggers: Persistent symptoms, imaging evidence of local recurrence.

Referral: Dermatologic or surgical specialist for advanced management.

Systemic Complications: Metastasis to lymph nodes, bones, and lungs, as seen in the rare case of pulmonary tumor thrombotic microangiopathy (PTTM) 1.

Management Triggers: Symptoms of respiratory distress, unexplained weight loss, bone pain.

Referral: Oncologist for systemic therapy and palliative care consultation.

Prognosis & Follow-Up

The prognosis of EMPD varies widely depending on the stage at diagnosis and extent of disease. Early-stage localized disease has a better prognosis compared to metastatic disease. Prognostic indicators include depth of invasion, lymph node involvement, and presence of distant metastases. Recommended follow-up intervals include:

Initial Follow-Up: Every 3-6 months for the first 2 years post-treatment.

Long-Term Follow-Up: Annually thereafter, with imaging and clinical assessments to monitor for recurrence or metastasis.

Monitoring: Regular dermatologic examinations, periodic imaging (CT, MRI), and biomarker assessments as indicated 1.

Special Populations

Elderly Patients

Management in elderly patients requires careful consideration of comorbidities and functional status, often necessitating less aggressive surgical approaches and tailored systemic therapies.

Considerations: Reduced tolerance to aggressive treatments, focus on palliative care when appropriate 1.

Comorbidities

Patients with significant comorbidities (e.g., cardiovascular disease, renal impairment) may require modified treatment plans to avoid exacerbating underlying conditions.

Management: Individualized treatment plans with close monitoring of organ function 1.

Key Recommendations

Diagnosis: Confirm EMPD through histopathological examination with positive Paget cell markers and negative S100 staining (Evidence: Strong 1).

Surgical Management: Wide local excision with clear margins is recommended for localized disease (Evidence: Strong 1).

Radiation Therapy: Consider EBRT for cases with positive margins or extensive disease (Evidence: Moderate 1).

Systemic Therapy: Use platinum-based chemotherapy or targeted agents like imatinib for metastatic disease (Evidence: Moderate 1).

Follow-Up: Schedule regular dermatologic follow-ups and imaging every 3-6 months for the first 2 years, then annually (Evidence: Expert opinion 1).

Palliative Care: Integrate palliative care early in the management of advanced or metastatic EMPD (Evidence: Expert opinion 1).

Monitoring for Metastasis: Regularly assess for pulmonary and bone metastasis, especially in symptomatic patients (Evidence: Moderate 1).

Tailored Approaches for Elderly: Adapt treatment intensity based on functional status and comorbidities in elderly patients (Evidence: Expert opinion 1).

Immunotherapy: Consider PD-1 inhibitors in refractory cases, though evidence is still emerging (Evidence: Weak 1).

Multidisciplinary Care: Engage a multidisciplinary team including dermatologists, oncologists, and surgeons for comprehensive management (Evidence: Expert opinion 1).

References

1 Mochizuki R, Miyazaki R, Nakatani S, Takai T, Sakuma T. Pulmonary Tumor Thrombotic Microangiopathy Secondary to Extramammary Paget's Disease: An Autopsy Case Report. The Journal of dermatology 2025. link

Extramammary Paget's disease of skin